Patient-derived organoids for the personalized treatment of pancreatic neuroendocrine tumor with liver metastases: A case report

Figure 1 Computed tomography images of the patient before treatment, after transarterial chemoembolization, 2 months and 18 months after surgery. The orange arrows point to the liver lesions, and the yellow arrows point to the pancreatic lesions. TACE: Transarterial chemoembolization.

Figure 2  The growth status of organoids from liver metastatic lesions in a pancreatic neuroendocrine tumor patient.

Figure 3 Immunohistochemical and hematoxylin and eosin staining results of the liver puncture tissue from a patient with pancreatic neuroendocrine tumors. CK: Cytokeratin; CD: Cluster of differentiation; CgA: Chromogranin A; Syn: Synapsin; SSTR2: Somatostatin receptor 2; ATRX: X-linked alpha-thalassemia/mental retardation syndrome; HE: Hematoxylin and eosin.

Figure 4 The growth status of organoids from liver metastatic lesions drug sensitivity testing result. FOLFIRI: Folinic acid, fluorouracil, and irinotecan; mFOLFOX6: Modified folinic acid, fluorouracil, and oxaliplatin 6.